Assessment of Atrial Late Potentials in Patients with Hypertention to Investigate the Preventive Effect of Eplerenone on Atrial Fibrillation.

Assessment of Atrial Late Potentials in Patients with Hypertention to Investigate the Preventive Effect of Eplerenone on Atrial Fibrillation. - Assessment of Atrial Late Potentials in Patients with Hypertention to Investigate the Preventive Effect of Eplerenone on Atrial Fibrillation.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006343

Enrollment

Registered

2011-10-01

Start date

2011-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertention

Interventions

Eplerenone 25-100 mg daily for a period of 12 months Non-renin angiotensin aldosteron system blocker treatment initially using amlodipine 5 mg daily for a period of 12 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with hypertention who have not attained the target blood pressure level established by the Japan Society of hypertention 2009 guidelines. 2. Patients giving written consent on their own volition for participation in this clinical trial after being provided with sufficient explanation about the study.

Exclusion criteria

Exclusion criteria: 1. Patients who have a contraindication to Selara TAB administration. 2. Patients who have a contraindication to Norvasc TAB administration . 3. Patients with liver dysfunction (AST or ALT values of >=100IU). 4. Patients who are judged by the investigator to be not eligible for enrollment in the study.

Design outcomes

Primary

Measure	Time frame
Change in atrial late potentials recorded by P wave signal-averaged ECG.	—

Secondary

Measure	Time frame
1. Correlation between baseline characteristics and atrial late potentials. 2. Correlation between change in atrial late potentials and change in blood biomarkers.	—

Countries

Japan

Contacts

Public ContactMasato Kawasaki

Osaka General Medical Center Division of Cardiology

bpbhm701@yahoo.co.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026